Select a medication above to begin.
propafenone
generic
Black Box Warnings .
Increased Mortality
excessive mortality or nonfatal cardiac arrest rate (7.7% encainide/flecainide vs. 3% placebo) in asymptomatic non-life-threatening ventricular arrhythmias w/ MI 6 days - 2 years prior; avoid use in asymptomatic and symptomatic non-life-threatening ventricular arrhythmias, no survival benefit observed
Adult Dosing .
Dosage forms: ER CAP: 225 mg, 325 mg, 425 mg; TAB: 150 mg, 225 mg, 300 mg
atrial fibrillation/flutter
- [maintenance rhythm control, immediate-release form]
- Dose: 150-300 mg PO q8h; Start: 150 mg PO q8h, may incr. to 225 mg PO q8h, then 300 mg PO q8h in >3-4 day intervals; Max: 900 mg/day
- [maintenance rhythm control, extended-release form]
- Dose: 225-425 mg ER PO q12h; Start: 225 mg ER PO q12h, may incr. to 325 mg ER PO q12h, then 425 mg ER PO q12h in >5 day intervals; Info: do not open ER cap
- [cardioversion, <70 kg (off-label)]
- Dose: 450 mg PO x1
- [cardioversion, >70 kg (off-label)]
- Dose: 600 mg PO x1
PSVT
- [immediate-release form]
- Dose: 150-300 mg PO q8h; Start: 150 mg PO q8h, may incr. to 225 mg PO q8h, then 300 mg PO q8h in >3-4 day intervals; Max: 900 mg/day
- [extended-release form (off-label)]
- Dose: 225-425 mg PO q12h; Start: 225 mg PO q12h; Max: 850 mg/day
ventricular arrhythmias
- [150-300 mg PO q8h]
- Start: 150 mg PO q8h, may incr. to 225 mg PO q8h, then 300 mg PO q8h in >3-4 day intervals; Max: 900 mg/day
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [see below]
- hepatic impairment: consider decr. usual dose
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.